banter and General Discussion, page-10055

First 10055 Last

Share
Profile

Follow
col69

15,714 Posts.

5744

01/07/24

14:37

Post #: 74550033
Share

Originally posted by JB1975 ↑

End of the quarter no?

Should be an announcement about a BLA resubmission then, no?

I'm assuming no announcement is no resubmission yet as previously they have been announced when they've happened - but also previously they've been rescheduled later as well.

I read some links around one of LearningEachDays posts that gave me some background on a case within the FDA where one of the higher-ups Janet Woodcroft or Woodford or something overruled the principal investigators and an ODAC panel to grant a approval for a product in muscular dytrophy I think.

Only way I see the FDA saying what MSB alleges they've said especially as Silviu is reported to have said is if the FDA has similarly had internal over-ruling of scientists like Matt Klinker.

I think MSB is in a bubble (share price wise) and Cynata is (irrationally) bubbling along with it. If the FDA grants a BLA on the weak evidence MSB has provided I think it will harm the field (cell medicines) and the FDA will have a made a mess - succumbing to politicking and patient advocacy groups (perhaps they really have swayed Peter Marks - but they shouldn't have been able to on - not on the evidence MSB has put up).

MSB should have done an adult trial as the FDA were previously, sensibly, suggesting if not stating they should. I don't know if Peter Marks or others have the FDA have folded - its possible - but I hope not.

I do want MSB to get a BLA when they deserve to get it - but not before. If they get it before and without deserving it it will make for very bad policy and everyone coming afterwards will have to work around very bad policy. Which will slow down the delivery of affordable cell medicines.

Shareholders might cheer about the moats they've erected around themselves and then discover they'll die ahead of the medicines that they might have lived to see had the moats not been there.

Expand

If the FDA grants a BLA on the weak evidence MSB has provided

ROFL .... So you've seen the entire Remestemcel-L BLA resubmission document have you ? .... I mean no other HC posters have ?

Some of the comments you make that are stated/implied as facts are totally laughable just like the one above ... enough said

MSB Price at posting: 97.0¢ Sentiment: Buy Disclosure: Held
17 Upvote

1 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Finance school vs reality: What they don't teach you about the stock market

Making money: How many microcaps should be in an investor's portfolio?

There are more pages in this discussion • 2,095 more messages in this thread...

First 10055 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.31		Change 0.040(3.16%)		Mkt cap ! $1.490B

Open	High	Low	Value	Volume
$1.28	$1.32	$1.26	$3.433M	2.652M

Buyers (Bids)

No.	Vol.	Price($)
2	39558	$1.30

Sellers (Offers)

Price($)	Vol.	No.
$1.31	21776	3

View Market Depth

No.	Vol.	Price($)
2	39558	1.300
3	26433	1.295
6	108207	1.290
2	47468	1.285
3	10889	1.280

Price($)	Vol.	No.
1.310	21776	3
1.315	57441	5
1.320	2500	1
1.325	61160	4
1.330	15000	2

Last trade - 16.10pm 28/10/2024 (20 minute delay)

MSB (ASX) Chart

banter and General Discussion, page-10055

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Finance school vs reality: What they don't teach you about the stock market

Making money: How many microcaps should be in an investor's portfolio?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

banter and General Discussion, page-10055

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Finance school vs reality: What they don't teach you about the stock market

Making money: How many microcaps should be in an investor's portfolio?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News